{"database": "lobbying", "table": "lobbying_activities", "rows": [[2967103, "429558b6-a989-4735-adbc-16d6f2738280", "Q1", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2023, "first_quarter", "CPT", "Patent abuse issues. Affordable Prescriptions for Patients Act of 2023. Interagency Patent Coordination Act. Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025). Joint USPTO-FDA Collaboration Initiatives. Notice of Public Listening Session and Request for Comment (PTO-P-2022-0037).", "Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE", 50000, null, 0, 0, "2023-04-19T09:54:17-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2967103"], "units": {}, "query_ms": 2.6569559995550662, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}